Study On Therapy Effect Of Bone Marrow Derived Mesenchymal Stem Cell Combined Vitamin E Against Acute Kidney Injury

Acute kidney injury (AKI) is common in critically ill patients, caused by nephrotoxicitydrug, acute ischemia, and so on. In recently years, many human diseases were controlled withthe development of medical technique. However, the therapy method of this disease is still notimproved and AKI is associated with a substantially increased morbidity and mortality. Thus,it holds important significance to develop a new model to treat AKI.Stem cell technology is one of the most advanced technologies in the regenerativemedicine. In recent years, stem cell therapy was regarded as a kind of novel strategies forvarious diseases. This strategy is accepted by lots of researches for its little side effect andobvious therapy effect, and has the potential to be more effective than traditional drugtherapies. Especially, the bone marrow derived mesenchymal stem cells (BMSCs), have beenapplied in the therapy of kinds of disease for their maneuverability in obtaining and culture,including the therapy of AKI.In this study, Gentamicin was used as a damage factor in the culture of renal tubularepithelial cells (RTECs) in vitro, and to induce AKI in vivo. Through inhabiting damagedfactors and repairing kidney tissue, BMSCs combined with vitamin E were used for therapyin vivo and in vitro. The results showed that proliferating ability of RTECs was improved byBMSCs or vitamin E, especially for the combined group (P＜0.05). The treated rats incombined group (BMSCs3.3×106cells/kg+vitamin E80mg/kg) presented the lowest serumcreatinine and the highest urea nitrogen compared to non-treated rats. The improvement inrenal pathological changes was followed by less necrosis, degeneration and expansion ofrenal tubule. Under transmission electron microscope, unclear cell structure and reduction ofendoplasmic reticulum in the kytoplasm of RTECs were ameliorated with the treatment. Theapoptosis genes, Caspase3, caspase9and Fas were up-regulated in model group whiledown-regulated with the therapy. The combined group showed best inhabitation of Caspase9and Fas expression. Further analysis showed that the two treatments may act independently with each other. No joint action exists between BMSCs and vitamin E.In conclusion, our data demonstrated that both BMSC and vitamin E hold therapeuticaction to AKI induced by gentamicin. Especially, the combined treatment is better than BMSCor vitamin E alone. Therefore, not only this study develop a new therapy model for AKI, butalso the therapy model holds significant potential in clinical study for the little side effect andthe economy of vitamin E.